Search

Your search keyword '"De March, Elena"' showing total 17 results
Start Over Author "De March, Elena"
17 results on '"De March, Elena"'

1. A successful treatment-free remission is achievable also by chronic myeloid leukemia patients lacking optimal requirements

Author

Bonifacio, Massimiliano, Scaffidi, Luigi, Miggiano, Maria Cristina, Facchinelli, Davide, Tosoni, Luca, Pezone, Sara, Griguolo, Davide, Ciotti, Giulia, Danini, Marco, Bernardelli, Andrea, Bresciani, Rita, Cavraro, Monica, Crosera, Lara, De March, Elena, Dell’Eva, Michele, Dorotea, Laura, Frison, Luca, Furlani, Lara, Gianesello, Ilaria, Lovato, Ester, Marchetti, Elena, Morelli, Gianluca, Mullai, Rikard, Pizzano, Umberto, Zoletto, Simone, Fanin, Renato, Krampera, Mauro, Trentin, Livio, Calistri, Elisabetta, Carli, Giuseppe, Binotto, Gianni, and Tiribelli, Mario

Published
2024
Full Text
View/download PDF

2. A real-life study of daratumumab-bortezomib-dexamethasone (D-VD) in lenalidomide exposed/refractory multiple myeloma patients: a report from the Triveneto Myeloma Working Group

Author

Barilà, Gregorio, Quaglia, Francesca Maria, Furlan, Anna, Pescosta, Norbert, Bonalumi, Angela, Marcon, Chiara, Pascarella, Anna, Tinelli, Martina, De March, Elena, Lico, Albana, Sartori, Roberto, Clissa, Cristina, De Sabbata, Giovanni, Nappi, Davide, Porrazzo, Marika, De Marchi, Roberta, Pavan, Laura, Tosetto, Alberto, Gherlinzoni, Filippo, Krampera, Mauro, Bassan, Renato, Patriarca, Francesca, Semenzato, Gianpietro, and Zambello, Renato

Published
2024
Full Text
View/download PDF

3. A real-life study of daratumumab-bortezomib-dexamethasone (D-VD) in lenalidomide exposed/refractory multiple myeloma patients: a report from the Triveneto Myeloma Working Group

Author

Barilà, Gregorio, primary, Quaglia, Francesca Maria, additional, Furlan, Anna, additional, Pescosta, Norbert, additional, Bonalumi, Angela, additional, Marcon, Chiara, additional, Pascarella, Anna, additional, Tinelli, Martina, additional, De March, Elena, additional, Lico, Albana, additional, Sartori, Roberto, additional, Clissa, Cristina, additional, De Sabbata, Giovanni, additional, Nappi, Davide, additional, Porrazzo, Marika, additional, De Marchi, Roberta, additional, Pavan, Laura, additional, Tosetto, Alberto, additional, Gherlinzoni, Filippo, additional, Krampera, Mauro, additional, Bassan, Renato, additional, Patriarca, Francesca, additional, Semenzato, Gianpietro, additional, and Zambello, Renato, additional

Published
2023
Full Text
View/download PDF

4. STAT3 mutation impacts biological and clinical features of T-LGL leukemia

Author

Teramo, Antonella, primary, Barilà, Gregorio, additional, Calabretto, Giulia, additional, Ercolin, Chiara, additional, Lamy, Thierry, additional, Moignet, Aline, additional, Roussel, Mikael, additional, Pastoret, Cédric, additional, Leoncin, Matteo, additional, Gattazzo, Cristina, additional, Cabrelle, Anna, additional, Boscaro, Elisa, additional, Teolato, Sara, additional, Pagnin, Elisa, additional, Berno, Tamara, additional, De March, Elena, additional, Facco, Monica, additional, Piazza, Francesco, additional, Trentin, Livio, additional, Semenzato, Gianpietro, additional, and Zambello, Renato, additional

Published
2017
Full Text
View/download PDF

5. Diffusion Weighted Whole Body MRI for Evaluation of Early Response in Multiple Myeloma

Author

Zambello, Renato, primary, Barilà, Gregorio, additional, Crimì, Filippo, additional, Annamaria, Guolo, additional, Vio, Stefania, additional, Ponzoni, Alberto, additional, Lico, Albana, additional, Branca, Antonio, additional, Berno, Tamara, additional, De March, Elena, additional, Ammirati, Lucia, additional, Leoncin, Matteo, additional, De Biasi, Ercole, additional, Semenzato, Gianpietro, additional, and Lacognata, Carmelo, additional

Published
2017
Full Text
View/download PDF

6. Infections in Multiple Myeloma: An Understimate Risk Factor of Comorbidity

Author

Barilà, Gregorio, primary, Compagno, Nicolo', additional, Lico, Albana, additional, Cinetto, Francesco, additional, Berno, Tamara, additional, De March, Elena, additional, Branca, Antonio, additional, Ammirati, Lucia, additional, Leoncin, Matteo, additional, Agostini, Carlo, additional, Semenzato, Gianpietro, additional, and Zambello, Renato, additional

Published
2017
Full Text
View/download PDF

7. Hyperammonemic Encephalopathy as Initial Presentation of Multiple Myeloma

Author

Lico, Albana, primary, Barilà, Gregorio, additional, Gaiani, Alessandra, additional, Pompanin, Sara, additional, Berno, Tamara, additional, Ammirati, Lucia, additional, Leoncin, Matteo, additional, Branca, Antonio, additional, De March, Elena, additional, Briani, Chiara, additional, Cagnin, Annachiara, additional, Semenzato, Gianpietro, additional, and Zambello, Renato, additional

Published
2017
Full Text
View/download PDF

8. Lenalidomide long-term neurotoxicity

Author

Dalla Torre, Chiara, primary, Zambello, Renato, additional, Cacciavillani, Mario, additional, Campagnolo, Marta, additional, Berno, Tamara, additional, Salvalaggio, Alessandro, additional, De March, Elena, additional, Barilà, Gregorio, additional, Lico, Albano, additional, Lucchetta, Marta, additional, Ermani, Mario, additional, and Briani, Chiara, additional

Published
2016
Full Text
View/download PDF

9. Cytogenetic Impact on Lenalidomide Treatment in Relapsed/Refractory Multiple Myeloma: A Real-Life Evaluation

Author

Zambello, Renato, primary, Bonaldi, Laura, additional, Berno, Tamara, additional, Martines, Annalisa, additional, Sechettin, Erica, additional, De March, Elena, additional, Branca, Antonio, additional, Lico, Albana, additional, Minotto, Claudia, additional, Briani, Chiara, additional, Gurrieri, Carmela, additional, Temporin, Francesca, additional, Battistutta, Claudia, additional, Piazza, Francesco, additional, Cavraro, Monica, additional, Trentin, Livio, additional, and Semenzato, Gianpietro, additional

Published
2015
Full Text
View/download PDF

11. T Large Granular Lymphocytes Leukemia (T-LGLL) and Natural Killer Chronic Lymphoproliferative Disorder (NK-CLPD): Two Diseases With a Common Etiopathogenetic Mechanism?

Author

Gattazzo, Cristina, primary, Teramo, Antonella, additional, Nardin, Chiara, additional, Passeri, Francesca, additional, Barilà, Gregorio, additional, Trimarco, Valentina, additional, Pavan, Alberto, additional, Carraro, Samuela, additional, De March, Elena, additional, Facco, Monica, additional, Trentin, Livio, additional, Semenzato, Gianpietro, additional, and Zambello, Renato, additional

Published
2013
Full Text
View/download PDF

13. Lenalidomide long-term neurotoxicity.

Author

Torre, Chiara Dalla, Zambello, Renato, Cacciavillani, Mario, Campagnolo, Marta, Berno, Tamara, Salvalaggio, Alessandro, De March, Elena, Barilà, Gregorio, Lico, Albano, Lucchetta, Marta, Ermani, Mario, and Briani, Chiara

Published
2016
Full Text
View/download PDF

14. Posaconazole Prophylaxis in Patients Undergoing Chemotherapy for Acute Myeloid Leukemia: A Single Center Experience of Therapeutic Drug Monitoring.

Author

Pavan, Laura, primary, Loregian, Arianna, additional, Quinto, Angela Maria, additional, Maggio, Speranza Antonia Di, additional, Pagni, Silvana, additional, Gazzola, Marco, additional, De March, Elena, additional, Palù, Giorgio, additional, Semenzato, Gianpietro, additional, Trentin, Livio, additional, Vianello, Fabrizio, additional, and Zambello, Renato, additional

Published
2012
Full Text
View/download PDF

15. Evaluation of Therapy in Symptomatic Patients with Lymphoproliferative Disorders of Large Granular Lymphocytes in Italy

Author

Pavan, Laura, primary, Zanotti, Roberta, additional, De March, Elena, additional, Sissa, Cinzia, additional, Cavraro, Monica, additional, Leoni, Pietro, additional, Fragasso, Alberto, additional, Arcaini, Luca, additional, Intermesoli, Tamara, additional, Trentin, Livio, additional, Semenzato, Gianpietro, additional, and Zambello, Renato, additional

Published
2011
Full Text
View/download PDF

16. Bortezomib, Thalidomide and Lenalidomide: Have They Really Changed the Outcome of Multiple Myeloma?

Author

Mian M, Tinelli M, DE March E, Turri G, Meneghini V, Pescosta N, Berno T, Marabese A, Mondello P, Patriarca F, Pizzolo G, Semenzato G, Cortelazzo S, and Zambello R

Subjects
Bortezomib therapeutic use, Humans, Lenalidomide, Leukemia, Plasma Cell surgery, Multiple Myeloma surgery, Prognosis, Retrospective Studies, Stem Cell Transplantation, Survival Analysis, Thalidomide therapeutic use, Treatment Outcome, Bortezomib administration & dosage, Leukemia, Plasma Cell drug therapy, Multiple Myeloma drug therapy, Thalidomide administration & dosage, Thalidomide analogs & derivatives
Abstract

Treatment of multiple myeloma (MM) has significantly improved, although the disease remains incurable. Prospective clinical trials evaluating the impact on outcome of new drugs such as proteasome inhibitors or immunomodulating agents are limited since they are not able to reflect the clinical routine and available retrospective data are not detailed enough to directly evaluate the value of new drugs. To address these information gaps, we performed a retrospective real-life analysis. We retrospectively assessed 949 patients treated for multiple myeloma or plasma cell leukemia at three Italian cancer centers in the years 1979-2014. Clinical features at the time of diagnosis were consistent with what was observed in clinical routine. A total of 39% of patients underwent high-dose chemotherapy followed by autologous stem cell transplantation (ASCT). The median overall survival (OS) of the whole group was 5.4 years and ranged from 3.4 years for patients who did not receive at least one of the new drugs compared to 5.9 years in the other patients (p<0.001). The improvement in OS due to administration of new drugs was also observed among different prognostic sub-groups such as age, Durie and Salmon stage, international staging system and renal impairment. Availability of new drugs significantly improved survival of patients who underwent ASCT and also those who did not. In conclusion, we provided evidence that the advent of the new drugs drastically improved the outcome of patients with MM, also in cases with poor risk at the time of diagnosis. ASCT is still of major importance in the treatment of this disease. Nevertheless, MM remains incurable and new therapeutic approaches are warranted., (Copyright© 2016 International Institute of Anticancer Research (Dr. John G. Delinassios), All rights reserved.)

Published
2016

17. Detection of monoclonal T populations in patients with KIR-restricted chronic lymphoproliferative disorder of NK cells.

Author

Gattazzo C, Teramo A, Passeri F, De March E, Carraro S, Trimarco V, Frezzato F, Berno T, Barilà G, Martini V, Piazza F, Trentin L, Facco M, Semenzato G, and Zambello R

Subjects
Adult, Aged, Aged, 80 and over, Chronic Disease, Cohort Studies, Disease Progression, Female, Flow Cytometry, Follow-Up Studies, Gene Rearrangement, Humans, Immunophenotyping, Killer Cells, Natural metabolism, Killer Cells, Natural pathology, Leukemia, Large Granular Lymphocytic metabolism, Leukemia, Large Granular Lymphocytic pathology, Male, Middle Aged, Neoplasm Staging, Prognosis, Receptors, Antigen, T-Cell genetics, Receptors, Antigen, T-Cell metabolism, Receptors, KIR genetics, T-Lymphocytes metabolism, T-Lymphocytes pathology, T-Lymphocytes, Cytotoxic metabolism, T-Lymphocytes, Cytotoxic pathology, Killer Cells, Natural immunology, Leukemia, Large Granular Lymphocytic immunology, Receptors, KIR metabolism, T-Lymphocytes immunology, T-Lymphocytes, Cytotoxic immunology
Abstract

The etiology of chronic large granular lymphocyte proliferations is largely unknown. Although these disorders are characterized by the expansion of different cell types (T and natural killer) with specific genetic features and abnormalities, several lines of evidence suggest a common pathogenetic mechanism. According to this interpretation, we speculated that in patients with natural killer-type chronic lymphoproliferative disorder, together with natural killer cells, also T lymphocytes undergo a persistent antigenic pressure, possibly resulting in an ultimate clonal T-cell selection. To strengthen this hypothesis, we evaluated whether clonal T-cell populations were detectable in 48 patients with killer immunoglobulin-like receptor-restricted natural killer-type chronic lymphoproliferative disorder. At diagnosis, in half of the patients studied, we found a clearly defined clonal T-cell population, despite the fact that all cases presented with a well-characterized natural killer disorder. Follow-up analysis confirmed that the TCR gamma rearrangements were stable over the time period evaluated; furthermore, in 7 patients we demonstrated the appearance of a clonal T subset that progressively matures, leading to a switch between killer immunoglobulin-like receptor-restricted natural killer-type disorder to a monoclonal T-cell large granular lymphocytic leukemia. Our results support the hypothesis that a common mechanism is involved in the pathogenesis of these disorders., (Copyright© Ferrata Storti Foundation.)

Published
2014
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results